A Study on Nutrition Support Therapy of Patients With Liver Failure

A Clinic Trail on Nutrition Support Therapy of Patients With Liver Failure

Status

UNKNOWN

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT03944330

Enrollment

100

Registered

2019-05-09

Start date

2019-05-10

Completion date

2022-06-01

Last updated

2019-05-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Nutrition

Brief summary

This study is a Clinical trial to assess the efficacy of nutrition support therapy of patients with liver failure. Patients were randomized to one of 2 groups to receive different nutrition and energy support treatment.

Detailed description

Patients with liver failure (defined by APASL) induced by any precipitating factors were randomized to two groups; a treatment group and a control group. Participants in treatment group were provided with a standard hospital diet that provided 25-30 kcal/kg/day . Patients in control group receive diet guide

Interventions

DIETARY_SUPPLEMENTstandard hospital diet

patients were provided standard hospital diet that provided 25-30 kcal/kg/day

Study design

Allocation

NON_RANDOMIZED

Intervention model

PARALLEL

Primary purpose

SUPPORTIVE_CARE

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to 65 Years

Healthy volunteers

Inclusion criteria

1. Male and female patients from 18 to 65 years of age; 2. Patient inclusion criteria: jaundice (serum total bilirubin ≥5 mg/dl) and coagulopathy (INR ≥ 1.5 or prothrombin activity ≥ 40 %), accompanied by ascites and/or encephalopathy within 4 weeks.

Exclusion criteria

1. Surgery with in 4 weeks 2. three degree hepatoencephalopathy 3. malignant tumors 4. cardiac failure or respiratory failure 5. liver transplantation within observing period -

Design outcomes

Primary

Measure	Time frame	Description
Mortality at 30 day	4 weeks	The percentage of death of liver failure patients at 4 weeks

Secondary

Measure	Time frame	Description
liver transplant-free survival	3month	survival rate on 4 weeks and 3 month
Laboratory variables on serum biochemistry markers	3month	Laboratory variables on serum lever of glutamic-pyruvic transaminase/glutamic oxalacetic transaminase/total bilirubin/ cholinesterase will be combined to report liver function
Laboratory variables on fasting blood sugar	3month	Laboratory variables on serum lever of fasting blood sugar

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026